NCT06905626

Brief Summary

The investigators believe they key to effective prevention of obesity is early identification of individuals at high risk of excess weight gain and proactive implementation of a comprehensive approach including lifestyle-based coaching and preventive medical management targeting the pathophysiology of dysregulated energy metabolism. In this study the investigators will take a fundamentally different approach to the science of obesity prevention by targeting the underlying biological processes driving unhealthy weight gain in adolescents/young adults (AYAs), a group that has been underrepresented in medication trials.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P25-P50 for phase_3 healthy-volunteers

Timeline
59mo left

Started Jun 2026

Longer than P75 for phase_3 healthy-volunteers

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 4, 2025

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 1, 2025

Completed
1.2 years until next milestone

Study Start

First participant enrolled

June 1, 2026

Expected
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2030

1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2031

Last Updated

February 17, 2026

Status Verified

February 1, 2026

Enrollment Period

3.8 years

First QC Date

February 4, 2025

Last Update Submit

February 13, 2026

Conditions

Keywords

Obesity prevention

Outcome Measures

Primary Outcomes (1)

  • BMI

    Change in body mass index

    24 months

Secondary Outcomes (1)

  • Diet quality and eating behaviors

    24 months

Study Arms (2)

Qsymia arm

EXPERIMENTAL

Qsymia

Drug: Qsymia 7.5 miligrams (mg)-46 mg Extended Release Capsule

Placebo arm

PLACEBO COMPARATOR

Placebo

Drug: Placebo

Interventions

Qsymia

Also known as: Qsymia
Qsymia arm

Placebo

Placebo arm

Eligibility Criteria

Age18 Years - 25 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18 to M 25 at screening
  • BMI \>/= 25 to \< 30 kg/m\^2
  • Family history of obesity defined as one biological parent with severe obesity (BMI \>/= 35) and/or two biological parents with obesity (BMI \>/=30). Parental obesity status will be confirmed by obtaining a release of information to review and electronic health record.

You may not qualify if:

  • Tanner stage 1-4
  • Diabetes (type 1 or 2)
  • Current or recent (\<6 months prior to screening) use of anti-obesity medication(s) or other weight-altering medication(s) (e.g. atypical anti-psychotics, attention deficit hyperactivity disorder (ADHD) stimulant)
  • Previous bariatric surgery
  • Current or recent (\<6 months prior to screening) use of medication(s) to treat insulin resistance
  • Recent initiation (\<3 months prior to screening) of anti-hypertensive or lipid medication(s)
  • History of glaucoma
  • Current or recent (\<14 days prior to screening) use of monoamine oxidase inhibitor
  • Known hypersensitivity to sympathomimetic amines
  • History of treatment with growth hormone
  • Patient Health Questionnaire-9 (PHQ-9) score of \>/= 15 at screening
  • Eating disorder symptoms within 6 months and/or any past medical diagnosis of eating disorder
  • Major psychiatric disorder
  • Unstable clinically-diagnosed depression
  • History of suicide attempt
  • +18 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Qsymia

Study Officials

  • Aaron Kelly, PhD

    University of Minnesota

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Aaron Kelly, PhD

CONTACT

Lisa Hostetler

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
This study will have a 1:1 randomization. Participants will receive either Qsymia or a matching placebo.
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 4, 2025

First Posted

April 1, 2025

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

March 31, 2030

Study Completion (Estimated)

March 31, 2031

Last Updated

February 17, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

A long-term data sharing and preservation plan will be used to store and make publicly accessible the data beyond the life of the project. The deidentified data will be deposited into the Data Repository for University of Minnesota (DRUM). This University of Minnesota Libraries hosted institutional data repository is an open access platform for dissemination and archiving of university research data and is free to the University of Minnesota researchers. Curators review all incoming submissions and work with data authors to comply with data sharing requirements in ways that make data FAIR (Findable, Accessible, Interoperable, Reusable).

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
10 years
Access Criteria
U of Minnesota Libraries